Definium Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Definium Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- DFTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001813814
Board of directors
-
Andreas Krebs · DirectorSince 2023
-
Carol A. Vallone · DirectorSince 2023
-
David W. Gryska · DirectorSince 2023
-
Miri Halperin Wernli · Director · Executive PresidentSince 2023
-
Robert Barrow · Director · Chief Executive OfficerSince 2023
-
Roger Crystal · DirectorSince 2023
-
Suzanne Louise Bruhn · DirectorSince 2023
Chief executives
Robert Barrow
· Chief Executive Officer
Dates unknown
Board connections
1 of this board's directors also sit on 2 other boards.
- via Suzanne Louise Bruhn
- via Suzanne Louise Bruhn
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2025 | Robert Barrow Director, Officer (Chief Executive Officer) | Open-market sale | −21,208 | $6.74 | $142,942 |
| Mar 25, 2025 | Karlin Daniel Officer (Chief Medical Officer) | Open-market sale | −6,836 | $6.74 | $46,075 |
| Mar 25, 2025 | Sullivan Mark Officer (Chief Legal Officer) | Open-market sale | −6,576 | $6.74 | $44,322 |
| Mar 25, 2025 | Liao Carrie Officer (Chief Accounting Officer) | Open-market sale | −2,347 | $6.74 | $15,819 |
| Mar 12, 2025 | Karlin Daniel Officer (Chief Medical Officer) | Grant or award | +115,000 | — | — |
| Mar 12, 2025 | Robert Barrow Director, Officer (Chief Executive Officer) | Grant or award | +350,000 | — | — |
| Mar 12, 2025 | Sullivan Mark Officer (Chief Legal Officer) | Grant or award | +150,000 | — | — |
| Mar 12, 2025 | Liao Carrie Officer (Chief Accounting Officer) | Grant or award | +50,000 | — | — |
| Dec 26, 2024 | Robert Barrow Director, Officer (Chief Executive Officer) | Open-market sale | −19,106 | $7.43 | $141,958 |
| Dec 26, 2024 | Liao Carrie Officer (Chief Accounting Officer) | Open-market sale | −2,273 | $7.43 | $16,888 |
| Dec 26, 2024 | Karlin Dan Officer (Chief Medical Officer) | Open-market sale | −6,643 | $7.43 | $49,357 |
| Dec 26, 2024 | Sullivan Mark Officer (Chief Legal Officer) | Open-market sale | −4,519 | $7.43 | $33,576 |
| Dec 5, 2024 | David W. Gryska Director | Open-market purchase | +2,500 | $7.17 | $17,925 |
| Sep 25, 2024 | Liao Carrie Officer (Chief Accounting Officer) | Open-market sale | −2,352 | $5.98 | $14,065 |
| Sep 25, 2024 | Robert Barrow Director, Officer (Chief Executive Officer) | Open-market sale | −19,771 | $5.98 | $118,231 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.